These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 26744643)

  • 61. Use of the nonavalent HPV vaccine in individuals previously fully or partially vaccinated with bivalent or quadrivalent HPV vaccines.
    Van Damme P; Bonanni P; Bosch FX; Joura E; Kjaer SK; Meijer CJ; Petry KU; Soubeyrand B; Verstraeten T; Stanley M
    Vaccine; 2016 Feb; 34(6):757-61. PubMed ID: 26772631
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Optimal control with multiple human papillomavirus vaccines.
    Malik T; Imran M; Jayaraman R
    J Theor Biol; 2016 Mar; 393():179-93. PubMed ID: 26796222
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Numbers game: Researchers explore whether fewer than 3 doses of HPV vaccine are effective.
    Cancer; 2016 Jan; 122(1):11-2. PubMed ID: 26747465
    [No Abstract]   [Full Text] [Related]  

  • 64. Deconstructing the measure of vaccine efficacy against disease irrespective of HPV in HPV vaccine clinical trials.
    Bautista OM; Luxembourg A
    Contemp Clin Trials; 2016 Mar; 47():254-8. PubMed ID: 26795674
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Interstitial Pneumonia Associated with the Influenza Vaccine: A Report of Two Cases.
    Hibino M; Kondo T
    Intern Med; 2017; 56(2):197-201. PubMed ID: 28090052
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Safety of Human Papillomavirus Vaccines: An Updated Review.
    Phillips A; Patel C; Pillsbury A; Brotherton J; Macartney K
    Drug Saf; 2018 Apr; 41(4):329-346. PubMed ID: 29280070
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Interstitial lung disease associated with human papillomavirus vaccination.
    Yamamoto Y; Kazebayashi Y; Hirai N; Sasaki T; Ohsaki Y
    Respir Med Case Rep; 2015; 16():15-7. PubMed ID: 26744643
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Clinical update of the AS04-adjuvanted human papillomavirus-16/18 cervical cancer vaccine, Cervarix.
    Schwarz TF
    Adv Ther; 2009 Nov; 26(11):983-98. PubMed ID: 20024678
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years.
    Einstein MH; Baron M; Levin MJ; Chatterjee A; Edwards RP; Zepp F; Carletti I; Dessy FJ; Trofa AF; Schuind A; Dubin G;
    Hum Vaccin; 2009 Oct; 5(10):705-19. PubMed ID: 19684472
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine in HIV-positive women in South Africa: a partially-blind randomised placebo-controlled study.
    Denny L; Hendricks B; Gordon C; Thomas F; Hezareh M; Dobbelaere K; Durand C; Hervé C; Descamps D
    Vaccine; 2013 Nov; 31(48):5745-53. PubMed ID: 24091311
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in healthy boys aged 10-18 years.
    Petäjä T; Keränen H; Karppa T; Kawa A; Lantela S; Siitari-Mattila M; Levänen H; Tocklin T; Godeaux O; Lehtinen M; Dubin G
    J Adolesc Health; 2009 Jan; 44(1):33-40. PubMed ID: 19101456
    [TBL] [Abstract][Full Text] [Related]  

  • 72. AS04-adjuvanted human papillomavirus-16/18 vaccination: recent advances in cervical cancer prevention.
    Schwarz TF
    Expert Rev Vaccines; 2008 Dec; 7(10):1465-73. PubMed ID: 19053203
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study.
    Skinner SR; Szarewski A; Romanowski B; Garland SM; Lazcano-Ponce E; Salmerón J; Del Rosario-Raymundo MR; Verheijen RH; Quek SC; da Silva DP; Kitchener H; Fong KL; Bouchard C; Money DM; Ilancheran A; Cruickshank ME; Levin MJ; Chatterjee A; Stapleton JT; Martens M; Quint W; David MP; Meric D; Hardt K; Descamps D; Geeraerts B; Struyf F; Dubin G;
    Lancet; 2014 Dec; 384(9961):2213-27. PubMed ID: 25189358
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Pooled analysis of large and long-term safety data from the human papillomavirus-16/18-AS04-adjuvanted vaccine clinical trial programme.
    Angelo MG; David MP; Zima J; Baril L; Dubin G; Arellano F; Struyf F
    Pharmacoepidemiol Drug Saf; 2014 May; 23(5):466-79. PubMed ID: 24644063
    [TBL] [Abstract][Full Text] [Related]  

  • 75.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 76.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 77.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 78.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 79.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.